H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7

Connect Biopharma shares fell 40% over the past week to $1.24 after its Phase 2 Seabreeze STAT acute-asthma trial missed statistical significance on its treatment-failure primary endpoint. H.C. Wainwright maintained its Buy rating and $7.00 target, arguing that an unexpectedly low placebo event rate underpowered the study and that rademikibart still showed statistically significant lung-function improvement with no meaningful efficacy or safety concerns. Upcoming COPD data and potential FDA alignment on a registrational acute-asthma endpoint are the next potential catalysts.

Analysis

CNTB is now a binary regulatory-and-data vehicle rather than a conventional post-data valuation dislocation. A missed primary endpoint materially weakens the evidentiary package regardless of favorable secondary measures: regulators generally focus on prespecified endpoint success, and a placebo-rate explanation is only investable if the company can demonstrate that event-rate assumptions, site mix, and multiplicity—not drug effect—drove the miss. Sell-side targets are not independent validation; their implied upside largely assumes a recoverable development path.

The near-term setup is asymmetric but not cleanly bullish. COPD data later this month can either validate a broader anti-inflammatory signal and restore financing optionality, or confirm that efficacy is insufficiently robust across acute respiratory settings; the latter would raise dilution risk sharply for a sub-$100m development-stage issuer. An FDA endpoint-alignment update is a 1-3 month catalyst, but agreement on trial design does not establish approvability and could require a larger, more expensive study than current investors expect.

Contrarian view: the 40% decline may still understate the cost-of-capital consequence of a failed primary endpoint. Even if lung-function data are real, commercial differentiation against entrenched asthma/COPD biologics requires reproducible reductions in exacerbations, admissions, or rescue interventions—not only a physiologic readout. The key falsifier for the bearish residual thesis is a COPD dataset with statistically persuasive, clinically meaningful outcomes on a hard endpoint plus clear FDA confirmation that a feasible registrational program can proceed without another dose-finding detour.

Key Decisions for Investors

• No core long before the COPD readout; treat CNTB as an event-driven watch item, not a valuation long. Reassess only if COPD shows prespecified endpoint success and the company discloses cash runway through the next registrational inflection without near-term equity financing.
• For high-risk biotech capital, consider a small defined-loss long only after confirming liquid option availability; otherwise avoid chasing a post-gap rebound in a thinly capitalized equity. Size for potential 50%+ downside on a second ambiguous or negative dataset.
• Set an alert for an FDA meeting outcome: positive trade confirmation requires a disclosed registrational endpoint, sample-size framework, and timing. A vague statement of 'constructive dialogue' is insufficient and should not be treated as de-risking.
• Monitor comparable respiratory-biologic incumbents such as REGN, AZN, and GSK as competitive benchmarks rather than direct shorts. Their established franchises limit CNTB's eventual pricing power unless rademikibart demonstrates a clearly differentiated acute-care outcome.